drugset / Trial / NCT06095570

The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation

NCT06095570

RandomizedParallel-groupTriple-blindTreatment

Summary

Preliminary studies have illuminated the promising nature of ciprofol, indicating its enhanced safety spectrum, superior potency, and a diminished likelihood of experiencing injection-related discomfort. Venturing deeper, this research embarked on an ambitious quest to measure the 95% effective volume of ciprofol for induction of general anesthesia by a modified sequential method and juxtapose the 95% effective volume dosage of ciprofol against a corresponding dose of remimazolam during the initiation of general anesthesia. The study delved into diverse anesthetic protocols, meticulously scrutinizing the safety and efficacy credentials of ciprofol. The ultimate vision was to pave a robust foundation for the sophisticated and judicious utilization of ciprofol in clinical landscapes.

Timeline

Start
2022-07-23
Primary completion
2023-12-30
Completion
2023-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule Intravenous
Comparator Remimazolam Small molecule

Indications

No indication recorded.